20 Takeover Rumors Hedge Funds Are Buying

2. Insmed Incorporated (NASDAQ:INSM)

No. of Hedge Funds: 72

A biopharmaceutical company, Insmed Incorporated (NASDAQ:INSM), located in New Jersey, is focused on developing therapies for serious and rare diseases, including respiratory conditions. The company’s flagship product, Arikayce®, treats Mycobacterium avium complex (MAC) lung disease. Insmed Incorporated (NASDAQ:INSM) differentiates itself from its competitors, like Horizon Therapeutics, by covering unmet needs, late-stage pipeline assets, and global regulatory strategy. The company’s gene therapy and protein engineering research helps it take the lead in the orphan drug and pulmonary care markets.

Insmed Incorporated (NASDAQ:INSM)’s shares have more than doubled in 2024, prompting analysts to predict the company’s potential takeover in 2025. This conclusion is also partly based on the attractiveness of the company as a buyout target for larger biopharma companies focused on treating respiratory diseases. Near the end of 2024, the company applied with the NDA for the clearance of its lead pipeline candidate, brensocatib, in the chronic pulmonary disorder non-cystic fibrosis bronchiectasis (NCFBE). Upon approval, the drug is expected to generate sales of more than $5 billion, thus increasing its appeal to potential buyers in the industry in 2025.

Institutional interest in the stock remains strong, with Insider Monkey noting 72 hedge funds holding stakes in Insmed Incorporated (NASDAQ:INSM), reinforcing the idea of the company’s takeover.